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Colorectal cancer globally affects more than one million 
new persons each year, and kills more than 700.000. 
Nevertheless, its diagnosis is still largely based on invasive 
tissue sampling and gaps remain in the understanding of its 
pathogenesis, with complex combinations between lifestyle, 
genetics, epigenetics, chronic inflammation (IBD) and 
microbiota. Untargeted metabolomics is one of the 




An optimized and validated (NIST SRM 1950) 
comprehensive GC×GC-(HR)TOFMS method we developed 
and already applied successfuly in Crohn disease (article 
under review) was used. It also included an in-house QC 
system based on all study samples aliquots, control charts to 
guarantee high-quality data, and data processing based on 
multiple statistical techniques.  
Practically, we analyzed serum samples from patients 
affected by colorectal cancer (CRC, n = 18), by colorectal 
cancer in remission (R-CRC, n = 17), and samples from 
healthy patients matched for as many biases as possible (HC, 
n = 19 and R-HC, n = 17). The aim was to highlight 
candidate biomarkers able to discriminate between matched 
HC and CRC or R-CRC. 
After the selection process, the discrimination potential 
of the candidates was assessed using supervised and 
unsupervised models (PLS & OPLS / PCA and HCA), 
discriminant analysis and ROC curves, with overfitting of the 
experimental data avoided by re-sampling and test validation 
testing. 
The significant metabolites were identified using full 
mass spectrum, linear retention indices and accuracte mass 
provided by state-of-the-art high-resolution (HR) time-of-
flight mass spectrometry. Finally, confident identifications 
were used to study the main metabolic pathways altered in 




From 620 unique features automatically detected in the 
cumulative chromatogram of all samples, that covered more 
than 5 orders of signal magnitude, 589 were kept for their 
chromatographic quality after manual control. Data were 
scaled and corrected for the analytical variation measured in 
the QC samples, before statistical research lead to 
respectively 11 and 15 candidates for CRC and R-CRC, from 
which 6 and 11 could be annotated with level 2 confidence1. 
These most altered, i.e. significant, metabolites 
peformed quite well, albeit not perfectly, in discriminating 
the disease from healthy samples. Indeed, if OPLS-DA Q2 
was limited to 0.35 and 0.47 respectively for CRC and R-
CRC (permutation Q2 : 0.38 and 0.41), AUC was > 0.8 and 
0.9 and discriminant analysis p-values was < 0.00001 for 
both. Unexpectedly, R-CRC samples were easier to 
discriminate from matched healthy patients than CRC. The 
annotated candidates were associated to alterations of several 
pathways including pentose phopshate pathway, glycolysis 
or gluconeogenesis, synthesis and degradation of ketone 




Figure 1. HCA, PCA and OPLS plots for both CRC vs 




This study not only found novel candidate biomarkers 
for colorectal cancer, in active and remission states, it also 
produced potentially original pathological insights through 
the metabolic pathways altered. Moreover, it confirmed the 
capability of GC×GC-(HR)TOFMS and the global analytical 
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